Sucampo Pharmaceuticals Set to Join S&P SmallCap 600

NEW YORK, Feb. 17, 2017 /PRNewswire/ -- Sucampo Pharmaceuticals Inc. (NASD: SCMP) will replace Blue Nile Inc. (NASD: NILE) in the S&P SmallCap 600 effective at the open of Thursday, February 23. Blue Nile was taken private in a transaction completed today.

Sucampo Pharmaceuticals focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders. Headquartered in Rockville, MD, the company will be added to the S&P SmallCap 600 GICS (Global Industry Classification Standard) Pharmaceuticals Sub-Industry index.

Following is a summary of the change:

For more information about S&P Dow Jones Indices, please visit www.spdji.com

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500^® and the Dow Jones Industrial Average^®. More assets are invested in products based on our indices than based on any other provider in the world. With over 1,000,000 indices and more than 120 years of experience constructing innovative and transparent solutions, S&P Dow Jones Indices defines the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

FOR MORE INFORMATION:

Soogyung Jordan
Global Head of Communications
New York, USA
(+1) 212 438 2297
[email protected]

David Blitzer
Managing Director and Chairman of the Index Committee
New York, USA
(+1) 212 438 3907
[email protected]

SOURCE S&P Dow Jones Indices

Related Links

http://www.spdji.com